Discovery of novel cross-protective Rickettsia prowazekii T-cell antigens using a combined reverse vaccinology and in vivo screening approach

Vaccine

Volumn 32, Issue 39, 2014, Pages 4968-4976

  Caro Gomez, Erika ^a   Gazi, Michal ^a   Goez, Yenny ^a   Valbuena, Gustavo ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Reverse vaccinology; Rickettsia; Vaccine

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEASOME; RICKETTSIA PROWAZEKII VACCINE; RP 403 ANTIGEN; RP 403ANTIGEN; RP 598 ANTIGEN; RP 739 ANTIGEN; RP 739ANTIGEN; RP 778 ANTIGEN; SUBUNIT VACCINE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; HLA ANTIGEN CLASS 1; RICKETTSIA VACCINE;

ALGORITHM; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PROTECTION; HAPLOTYPE; IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROCESSING; RICKETTSIA PROWAZEKII; RICKETTSIA TYPHI; ANIMAL; IMMUNOLOGY;

ALGORITHMS; ANIMALS; ANTIGENS, BACTERIAL; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; RICKETTSIA PROWAZEKII; RICKETTSIAL VACCINES;

EID: 84906086480     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.089     Document Type: Article

References (39)

1. Walker D.H. The realities of biodefense vaccines against Rickettsia. Vaccine 2009, 27(Suppl. 4):D52-D55.
2. Azad A.F. Pathogenic rickettsiae as bioterrorism agents. Clin Infect Dis 2007, 45(Suppl. 1):S52-S55.
3. Feng H-M., Popov V.L., Yuoh G., Walker D.H. Role of T lymphocyte subsets in immunity to spotted fever group rickettsiae. J Immunol 1997, 158:5314-5320.
4. Walker D.H., Olano J.P., Feng H-M. Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. Infect Immun 2001, 69:1841-1846.
5. Walker D.H., Popov V.L., Feng H-M. Establishment of a novel endothelial target mouse model of a typhus group rickettsiosis: evidence for critical roles for gamma interferon and CD8T lymphocytes. Lab Invest 2000, 80:1361-1372.
6. Sumner J.W., Sims K.G., Jones D.C., Anderson B.E. Protection of guinea-pigs from experimental Rocky Mountain spotted fever by immunization with baculovirus-expressed Rickettsia rickettsii rOmpA protein. Vaccine 1995, 13:29-35.
7. Crocquet-Valdes P.A., Díaz-Montero C.M., Feng H.M., Li H., Barrett A.D., Walker D.H. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine 2001, 20:979-988.
8. Churilla A., Ching W.M., Dasch G.A., Human Carl M. T lymphocyte recognition of cyanogen bromide fragments of the surface protein of Rickettsia typhi. Ann N Y Acad Sci 1990, 590:215-220.
9. Li Z., Díaz-Montero C.M., Valbuena G., Yu X.J., Olano J.P., Feng H.M., et al. Identification of CD8 T-lymphocyte epitopes in OmpB of Rickettsia conorii. Infect Immun 2003, 71:3920-3926.
10. + T cell responses. J Immunol 2007, 178:6814-6820.
11. Moutaftsi M., Tscharke D.C., Vaughan K., Koelle D.M., Stern L., Calvo-Calle M., et al. Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol 2010, 5:221-239.
12. Gazi M., Caro-Gomez E., Goez Y., Cespedes M.A., Hidalgo M., Correa P., et al. Discovery of a protective Rickettsia prowazekii antigen recognized by CD8+ T Cells, RP884, using an in vivo screening platform. PLOS ONE 2013, 8:e76253.
13. Azad A.F. Relationship of vector biology and epidemiology of louse- and flea-borne rickettsioses. Biology of rickettsial diseases 1988, 51-62. CRC Press, Boca Raton. D.H. Walker (Ed.).
14. Walker D.H., Cain B.G. The rickettsial plaque. Evidence for direct cytopathic effect of Rickettsia rickettsii. Lab Invest 1980, 43:388-396.
15. Nielsen M., Lundegaard C., Worning P., Hvid C.S., Lamberth K., Buus S., et al. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 2004, 20:1388-1397.
16. Nielsen M., Lundegaard C., Worning P., Lauemøller S.L., Lamberth K., Buus S., et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003, 12:1007-1017.
17. Lin H.H., Ray S., Tongchusak S., Reinherz E.L., Brusic V. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 2008, 9:8.
18. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
19. Reche P.A., Reinherz E.L. Prediction of peptide-MHC binding using profiles. Methods Mol Biol 2007, 409:185-200.
20. He Y., Racz R., Sayers S., Lin Y., Todd T., Hur J., et al. Updates on the web-based VIOLIN vaccine database and analysis system. Nucleic Acids Res 2014, 42:D1124-D1132.
21. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005, 11:748-756.
22. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33:530-541.
23. Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009, 87:300-308.
24. Kohlmeier J.E., Woodland D.L. Immunity to respiratory viruses. Annu Rev Immunol 2009, 27:61-82.
25. Kremer M., Suezer Y., Volz A., Frenz T., Majzoub M., Hanschmann K.M., et al. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog 2012, 8:e1002557.
26. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
27. Goulder P.J.R., Watkins D.I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008, 8:619-630.
28. + T cell immunity. Science 2011, 334:475-480.
29. + T cells require perforin to kill target cells and provide protection in vivo. J Immunol 2008, 181:8595-8603.
30. Gilchuk P., Spencer C.T., Conant S.B., Hill T., Gray J.J., Niu X., et al. Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest 2013, 123:1976-1987.
31. Grubaugh D., Flechtner J.B., Higgins D.E. Proteins as T cell antigens: methods for high-throughput identification. Vaccine 2013, 31:3805-3810.
32. + T cell response. J Virol 2010, 84:10220-10229.
33. Tung J., Sant A.J. Orchestration of CD4T cell epitope preferences after multipeptide immunization. J Immunol 2013, 191:764-772.
34. McLeod M.P., Qin X., Karpathy S.E., Gioia J., Highlander S.K., Fox G.E., et al. Complete genome sequence of Rickettsia typhi and comparison with sequences of other Rickettsiae. J Bacteriol 2004, 186:5842-5855.
35. Ogata H., Audic S., Renesto-Audiffren P., Fournier P.E., Barbe V., Samson D., et al. Mechanisms of evolution in Rickettsia conorii and R. prowazekii. Science 2001, 293:2093-2098.
36. Dumler J.S., Walker D.H. Rocky mountain spotted fever - changing ecology and persisting virulence. N Engl J Med 2005, 353(August (6)):551-553.
37. Parola P., Paddock C.D., Raoult D. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. Clin Microbiol Rev 2005, 18(October (4)):719-756.
38. Oteo J.A., Portillo A. Tick-borne rickettsioses in Europe. Ticks Tick Borne Dis 2012, 3(December (5-6)):271-278.
39. Paddock C.D., Sumner J.W., Comer J.A., Zaki S.R., Goldsmith C.S., Goddard J., et al. Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the United States. Clin Infect Dis 2004, 38(March (6)):805-811.